Logo

CMMB

Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd. • NASDAQ
$2.62 ▲ 3.15% (+0.08)
Market Cap $16.13 M
52w High $9.84
52w Low $2.36
Dividend Yield 0%
P/E -1.82
Volume 54.38K
Outstanding Shares 6.16M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $2.262M ▼ $-2.057M ▲ 0% $-0.36 ▲ $-2.066M ▲
Q1-2025 $0 $3.487M ▲ $-3.323M ▼ 0% $-0.58 ▲ $-3.474M ▼
Q4-2024 $0 $3.213M ▼ $-2.963M ▲ 0% $-0.63 ▲ $-3.207M ▲
Q3-2024 $0 $3.71M ▼ $-3.483M ▲ 0% $-0.8 ▲ $-3.693M ▲
Q2-2024 $0 $3.768M $-3.631M 0% $-1.01 $-3.755M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $9.365M ▼ $11.129M ▼ $1.43M ▼ $9.699M ▼
Q1-2025 $10.563M ▼ $12.819M ▼ $2.426M ▼ $10.393M ▼
Q4-2024 $14.266M ▼ $16.964M ▼ $3.427M ▼ $13.537M ▼
Q3-2024 $19.378M ▲ $20.897M ▲ $4.579M ▲ $16.318M ▲
Q2-2024 $12.727M $14.544M $4.559M $9.985M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-2.057M ▲ $0 $0 $0 $0 $0
Q1-2025 $-3.323M ▼ $0 $0 $0 $0 $0
Q4-2024 $-2.963M ▲ $0 $0 $0 $0 $0
Q3-2024 $-3.483M ▲ $0 $0 $0 $0 $0
Q2-2024 $-3.631M $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement Chemomab is a classic early-stage biotech from an income-statement perspective: it has no product revenue and has reported steady operating and net losses over the past several years. Those losses reflect research and development spending and basic corporate overhead rather than any commercial operations. The overall level of losses appears relatively contained and fairly stable over time, not rapidly escalating, which suggests disciplined cost control. The earnings per share figures move around more sharply than the underlying loss levels, likely because of changes in share count and reverse splits rather than big changes in the actual business performance. In short, it is a pre-revenue R&D company burning money to develop its pipeline.

Balance Sheet

Balance Sheet The balance sheet is small but straightforward. Assets are limited and largely consist of cash and equivalents, with no meaningful tangible operating assets and no debt. Equity is positive but modest, which reflects accumulated losses over time. The absence of debt reduces financial risk but also means the company relies almost entirely on equity funding and potential future partnerships. The current asset and equity base looks adequate for a lean operation but not large relative to the cost and length of late-stage clinical trials, implying that future funding actions are likely as development progresses.

Cash Flow

Cash Flow Cash flows show a consistent pattern of cash outflows from operations and no inflows from a commercial business. The company is spending cash mainly on R&D and operating expenses, with little to no capital spending, which fits a virtual or asset-light biotech model. Free cash flow is negative each year and closely tracks operating cash flow, underscoring that the business is not yet self-funding and depends on external capital. The burn rate appears steady rather than sharply rising, but it still represents an ongoing draw on the cash balance and a key risk factor over time.

Competitive Edge

Competitive Edge Chemomab’s competitive position centers on a focused, high-specialty niche rather than breadth. It targets fibro-inflammatory diseases where treatment options are very limited, such as primary sclerosing cholangitis and systemic sclerosis, which enhances the potential value of a successful therapy. The company has a first-mover position in blocking the CCL24 protein and has built a meaningful patent portfolio around this approach, plus regulatory advantages like orphan and fast track status. These elements create a defensible moat if the drug succeeds. On the other hand, Chemomab is small, has essentially one lead asset, and competes indirectly with much larger pharmaceutical players exploring different mechanisms, so its position is promising but highly dependent on clinical outcomes and execution.

Innovation and R&D

Innovation and R&D Innovation is the core of Chemomab’s story. Its lead antibody, nebokitug, is designed to block CCL24 and simultaneously tackle both inflammation and fibrosis—an approach that could be differentiated in diseases driven by both processes. The company has invested heavily in understanding the underlying biology and has advanced nebokitug into late-stage development in primary sclerosing cholangitis with a streamlined Phase 3 path agreed with regulators, which is a major validation of its R&D work. It is also exploring systemic sclerosis and potentially other related conditions, which could broaden the opportunity if early results translate across indications. The flip side is classic biotech risk: the company is heavily reliant on one main program, and future value depends on clinical trial success, regulatory approvals, and the ability to secure partners or capital to fund continued R&D.

Summary

Chemomab is a small, clinical-stage biotech with no revenue, controlled but persistent losses, and a lean, cash-based balance sheet with no debt. Its entire business model is built around advancing a single lead asset, nebokitug, which targets a novel protein involved in both inflammation and fibrosis. The company enjoys meaningful scientific differentiation, patent protection, and regulatory advantages in diseases with high unmet need, giving it a potentially strong strategic position if trials are successful. At the same time, financials highlight ongoing cash burn and the likelihood of future funding needs, while concentration in one main program and competition from larger players underscore the high uncertainty that is typical for this stage of biotech development.

NEWS

November 24, 2025 · 8:00 AM UTC

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Read more

November 20, 2025 · 8:00 AM UTC

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

November 6, 2025 · 8:00 AM UTC

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Read more